Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Chronic Genotype 1 or 3 HCV Infection
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir (SOF)
+ ribavirin (RBV) in treatment-naive adults with chronic genotype 1 or 3 hepatitis C virus
(HCV) infection.